The interim data strongly de-risks the upLIFT study and supports ersodetug's efficacy in tumor HI, a registrational path. Traders should watch for full enrollment and topline results in H2 2026, as well as FDA engagement on the congenital HI path forward. The 75% analyst bullish consensus and $348M market cap suggest the stock may re-rate on this positive catalyst.
Price Chart
Executive Summary
Rezolute announced positive interim data from its Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism. 6 of 8 enrolled participants met the primary endpoint (≥50% reduction in IV glucose requirements), and all 6 achieved complete discontinuation of IV glucose. The study is 50% enrolled (8 of 16 planned participants), and topline results are expected in H2 2026. One participant withdrew for hospice care and is counted as a non-responder; no drug-related adverse events were reported.
Key Facts
- 6 of 8 enrolled participants met the primary endpoint (≥50% reduction in IV glucose requirements within 8-week pivotal treatment phase)
- All 6 responders achieved complete discontinuation of intravenous glucose requirements
- Study is 50% enrolled (8 of 16 planned participants); topline results expected H2 2026
- One participant withdrew for hospice care (Stage 4 metastatic colon cancer, ECOG 4) and is counted as a non-responder
- No drug-related adverse events or safety findings reported to date
- All participants completing the 8-week pivotal period elected to continue into the open-label extension (up to 6 months cumulative treatment)
Financial Impact
No financial figures provided in the filing. The positive interim data supports the drug's efficacy signal in tumor HI, a rare disease with high unmet need, and may increase the probability of regulatory success and commercial value.
Risk Factors
- Small sample size (8 participants) limits statistical reliability; one non-responder due to hospice withdrawal could raise questions about patient selection
- Topline results in H2 2026 may differ from interim data
- FDA path for congenital HI remains uncertain after the sunRIZE study miss
- Competing therapies or regulatory setbacks could limit commercial opportunity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-069206 |
| Document: tm2616579d1_ex99-1.htm | 0001104659-26-069206 |
| Document: 0001104659-26-069206-index-headers.html | 0001104659-26-069206 |
| Document: 0001104659-26-069206-index.html | 0001104659-26-069206 |
| Document: 0001104659-26-069206.txt | 0001104659-26-069206 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | DEF 14A | $3.86 | awaiting T+20 | — | $4.11 (+6.48%) |
Oct 14, 2026 13d ago | 8-K | $3.90 | awaiting T+20 | — | $4.11 (+5.38%) |
Oct 5, 2026 22d ago | 8-K | $4.33 | awaiting T+20 | — | $4.11 (−5.08%) |
Sep 24, 2026 4w ago | 8-K | $3.90 $3.86 | ▲ +1.15% | ▼ −0.32% | $4.11 (−5.38%) |
Sep 24, 2026 4w ago | Press Release | $3.90 $3.86 | ▲ +1.15% | ▼ −0.32% | $4.11 (−5.38%) |
Jul 21, 2026 14w ago | Press Release | $5.09 $4.66 | ▼ −8.45% | ▼ −11.01% | $4.11 (−19.25%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.86 $5.13 | ▲ +32.90% | ▲ +31.01% | $4.11 (+6.48%) |
Jun 4, 2026 20w ago | Press Release | $4.51 $4.91 | ▲ +8.87% | ▲ +10.24% | $4.11 (−8.87%) |
Jun 2, 2026 21w ago | 8-K | $4.00 $4.95 | ▲ +23.75% | ▲ +25.32% | $4.11 (+2.75%) |
May 12, 2026 24w ago | 8-K | $3.33 $3.86 | ▲ +15.92% | ▲ +16.53% | $4.11 (+23.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers